Afuco™ Anti-ERBB3 ADCC Recombinant Antibody (Elgemtumab), ADCC Enhanced (CAT#: AFC-TAB-422CQ)

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to ERBB3. Elgemtumab is a human monoclonal antibody that can be potentially used in the treatment of Cancers, head and neck. It binds to and locks HER3 in the inactive conformation and does not interfere with its interaction with neuregulin (NRG). The inactivated form of HER3 blocks the PI3K/Akt signaling pathway, thereby inhibiting cellular proliferation in HER2 or NRG expressing tumor cells.

Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
Subcellular Location and Protein Expression
Normal Tissue
RNA Expression

Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • ADCC enhanced antibody
  • Specificity
  • Human ERBB3
  • Species Reactivity
  • Human
  • Clone
  • Elgemtumab
  • Applications
  • ELISA, IHC, FC, IP, IF, BL
  • Conjugate
  • Unconjugated
  • Generic Name
  • Elgemtumab
  • Related Disease
  • Cancers, head and neck

Product Property

  • Purity
  • >95% by SDS-PAGE
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

  • Alternative Names
  • Erb-B2 Receptor Tyrosine Kinase 3; V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 3; Tyrosine Kinase-Type Cell Surface Receptor HER3; Human Epidermal Growth Factor Receptor 3; Proto-Oncogene-Like Protein C-ErbB-3; EC 2.7.10.1; HER3; Lethal Congenital Contracture Syndrome 2; P180-ErbB3; P45-SErbB3; P85-SErbB3; EC 2.7.10; MDA-BF-1; C-ErbB-3; C-ErbB3; ErbB3-S; ErbB-3; LCCS2

Related Resources

  • Biosimilar Overview
  • Related Diseases
  • Related Signaling Pathways
Please refer to Elgemtumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Elgemtumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Elgemtumab"

Anti-Human ERBB3 Recombinant Antibody (Elgemtumab)
Recombinant monoclonal antibody to ERBB3. Elgemtumab is a human monoclonal antibody that can be potentially used in the treatment of Cancers, head and neck. It binds to and locks HER3 in the inactive conformation and does not interfere with its interaction with neuregulin (NRG). The inactivated form of HER3 blocks the PI3K/Akt signaling pathway, thereby inhibiting cellular proliferation in HER2 or NRG expressing tumor cells.

See other products for "ERBB3"

Select a product category from the dropdown menu below to view related products.
Please select product type
Single-domain Antibody Humanized Antibody Immunotoxin Human Antibody Mouse Antibody Chimeric Antibody Recombinant Antibody Neutralizing Antibody Rabbit Monoclonal Antibody Fab Fragment Antibody ADCC Enhanced Antibody scFv Fragment Antibody

Customer Reviews and Q&As

Submit a review or a question

There are currently no Customer reviews or questions for AFC-TAB-422CQ. Click the button above to contact us or submit your feedback about this product.

Popular products with customers


For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
Cart
    Go to compare

    Go to compare